Department of Oral Pathology, Oral Medicine and Maxillofacial Imaging, Goldschleger School of Dental Medicine, Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel.
Department of Internal Medicine, Tel-Aviv Sourasky Medical Centre, Tel-Aviv, Israel.
Oral Dis. 2024 Apr;30(3):1669-1679. doi: 10.1111/odi.14567. Epub 2023 Mar 29.
The aim of the study was to analyze objective and subjective olfactory/gustatory function in post-COVID-19 infection (PCI).
Patients with past PCR-confirmed COVID-19 infection and persistent olfactory/gustatory complaints were investigated. Olfactory threshold and identification, gustatory detection, identification, and magnitude scaling were tested.
A total of 42 PCI subjects were compared to 41 age- and gender-matched controls with no COVID-19 history. All PCI tested had mild COVID-19 disease. Mean interval between COVID-19 confirmations to testing was 7.4 ± 3.1 months. PCI subjects complained of combined dysfunction in 85.7%, isolated olfactory or gustatory dysfunction in 7.1% each. Combined complaints were significantly higher in PCI (p < 0.001). Objective testing showed significantly higher prevalence of dysfunction in PCI versus controls for hyposmia (73.8%, 12.2%), anosmia (11.9%, 0%), odor identification (68.5%, 83.0%), hypogeusia (23% and 2.4%, respectively), and impaired magnitude scaling, (p < 0.05). All PCI subjects with hypogeusia had abnormal gustatory magnitude scaling.
While most PCI subjects complained of combined gustatory and olfactory dysfunction, objective testing showed in the majority an isolated single sense dysfunction, with a low level of agreement between subjective and objective findings. Abnormal objective results for all olfactory and gustatory functions tested may suggest a central rather than peripheral mechanism, although concomitant mechanisms cannot be excluded.
本研究旨在分析新冠病毒感染后(post-COVID-19 infection,PCI)患者的客观和主观嗅觉/味觉功能。
调查了既往经 PCR 确诊的 COVID-19 感染且持续存在嗅觉/味觉障碍的患者。测试了嗅觉阈值和识别、味觉检测、识别和强度分级。
将 42 例 PCI 患者与 41 名年龄和性别匹配、无 COVID-19 病史的对照组进行比较。所有 PCI 患者的 COVID-19 均为轻症。COVID-19 确诊与检测之间的平均间隔为 7.4±3.1 个月。PCI 患者中有 85.7%抱怨联合性功能障碍,嗅觉或味觉障碍各占 7.1%。PCI 患者的联合抱怨明显更高(p<0.001)。客观测试显示,PCI 患者的嗅觉减退(73.8%,12.2%)、嗅觉丧失(11.9%,0%)、气味识别(68.5%,83.0%)、味觉减退(23%和 2.4%)和味觉强度分级受损的发生率明显高于对照组(p<0.05)。所有味觉减退的 PCI 患者均存在味觉强度分级异常。
尽管大多数 PCI 患者抱怨联合的嗅觉和味觉功能障碍,但客观测试显示,大多数患者存在单一感觉障碍,主观和客观发现之间的一致性较低。所有测试的嗅觉和味觉功能的异常客观结果可能提示存在中枢而非外周机制,但不能排除同时存在的机制。